Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms
Polypharmacy (particularly, adding a non-benzodiazepine anxiolytic) was a more significant risk factor for ADRs when taking sertraline, compared to the carrier status of CYP2C19 gene polymorphisms.
Authors
- С. Н. Тучкова (ORCID: https://orcid.org/0009-0001-2744-2752)
- Anna Y. Basova (ORCID: https://orcid.org/0000-0002-5001-8554)
- Y. S. Shevchenko (ORCID: https://orcid.org/0000-0001-7790-9595)
- Mirzaev KB
- D. Ye. Ivashchenko
- Eugenia N. Shagovenko (ORCID: https://orcid.org/0009-0002-9016-5521)
- Dmitry Alekseevitch Sychev
- Vitaliy V. Sobur (ORCID: https://orcid.org/0000-0002-3162-2115)
- Sergey V. Grass
- Yulia V. Chernetsova
- Sergey I. Markov
- Rimma V. Kondratieva
- Ivan N. Korsakov
Institutions
- Russian Medical Academy of Continuous Professional Education (RU)
- Child, Adolescent and Family Mental Health (CA)
- Russian Scientific Center of Surgery (RU)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fphar.2026.1724521
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00